The US Food and Drug Administration granted clearances for various tests for infectious diseases, coagulation disorders, and drug susceptibility.

NEW YORK – Adaptive Biotechnologies on Thursday reported a 22 percent increase in Q3 revenues driven by an increase in minimal residual disease testing.

The firm said on Wednesday that it has been hiring key sales and marketing personnel as it prepares to ramp up sales in 2025 of its PreTRM proteomic test.

The firm had received notice last year that it was out of compliance with a requirement to maintain a minimum $15 million market value of publicly held shares.

The firm said that demand has increased for its 10-minute sepsis risk test as it can save lives, reduce hospital stays, and reduce healthcare costs.

In the wake of suspending guidance to review the business in the first quarter of the year, QuidelOrtho has restructured and resumed offering a financial outlook. Bio-Rad confirmed its full-year ...

The company reported on Tuesday that its revenues jumped 8 percent in North America and Europe during the third quarter but fell slightly in the rest of the world.

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

Revenues for BD's Life Sciences segment, which includes the Integrated Diagnostic Solutions and Biosciences business units, were up 1 percent to $1.34 billion. The firm's blood-based ClonoSeq test can ...

The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.

Similar to other firms, the firm said that it has been negatively impacted as customers in China wait for government stimulus funding to arrive.

NEW YORK — UK-based iFast Diagnostics said on Tuesday that it has raised $6.5 million in seed funding. The financing round was led by KHP Ventures and included EInk, Raw Ventures, and OKG Capital, as ...